Earl Martin Douglas

CIK: 0001362155

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ALLO

Allogene Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ALLO
Allogene Therapeutics, Inc.
Aug 21, 2026
Sale(S)
Direct
29.7K shares at avg. $2.12$63K
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
22.9K shares at avg. $1.76$40K
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Award(A)
Stock Option (Right to buy)
Direct
539.1K shares-
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Award(A)
Restricted Stock Unit
Direct
152.5K shares-
ALLO
Allogene Therapeutics, Inc.
Feb 3, 2025
Sale(S)
Direct
6.4K shares at avg. $1.71$11K
ALLO
Allogene Therapeutics, Inc.
Jan 24, 2025
Award(A)
Direct
144.9K shares-

		Type	Shares	Price		Ownership
Aug 21, 2026	ALLO Allogene Therapeutics, Inc.	Sale(S)	29,697	$2.12	$62,958	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Sale(S)	22,900	$1.76	$40,304	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	539,072	-	-	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Award(A) Restricted Stock Unit	152,480	-	-	Direct
Feb 3, 2025	ALLO Allogene Therapeutics, Inc.	Sale(S)	6,404	$1.71	$10,951	Direct
Jan 24, 2025	ALLO Allogene Therapeutics, Inc.	Award(A)	144,928	-	$0	Direct

1-6 of 6 transactions

About Douglas Earl Martin

Douglas Earl Martin (SEC CIK 0001362155) files insider reports with the SEC as SVP, General Counsel of Allogene Therapeutics, Inc. (ALLO).

Signal8 holds 4 ownership filings by Douglas Earl Martin, all Form 4s, filed between Jan 28, 2025 and Aug 25, 2026. Those filings report 6 transactions, from Jan 24, 2025 to Aug 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Douglas Earl Martin's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Douglas Earl Martin

Aug 21, 2026: Open-market sale of ALLO shares (Form 4, code S).
Feb 2, 2026: Open-market sale of ALLO shares (Form 4, code S).
Feb 2, 2026: Grants or awards of ALLO derivative securities (2 lines, Form 4, code A).
Feb 3, 2025: Open-market sale of ALLO shares (Form 4, code S).
Jan 24, 2025: Grant or award of ALLO shares (Form 4, code A).

Other insiders filing for Allogene Therapeutics, Inc. (ALLO)

Parker Geoffrey M., CHIEF FINANCIAL OFFICER
Roberts Zachary, President and CEO
Kazam Joshua A, Director
MESSEMER DEBORAH M., Director
Mayo Stephen, Director
SATO VICKI L, Director

How to read Form 4 transaction codes